G92.0 Immune effector cell-associated neurotoxicity syndrome

Name of the Condition

• Immune effector cell-associated neurotoxicity syndrome

Summary

Immune effector cell-associated neurotoxicity syndrome (ICANS) is a neurological condition that can occur following treatment with certain immunotherapies, particularly those involving immune effector cells like CAR T-cells. It is characterized by a range of neurologic symptoms resulting from inflammation or toxicity to the central nervous system.

Causes

ICANS is caused by the release of inflammatory cytokines and immune-mediated damage to the brain and nervous system, typically triggered by immunotherapy treatments that activate immune cells to target cancer cells. The exact mechanisms involve cytokine release and potential direct neurotoxic effects.

Risk Factors

• Receipt of immunotherapy, especially CAR T-cell therapy or other immune effector cell treatments
• Underlying cancer type and disease burden
• Prior history of neurologic conditions or central nervous system involvement
• Concomitant use of other medications that may affect neurologic function

Symptoms

• Altered mental status or confusion
• Aphasia (difficulty speaking or understanding language)
• Tremors or asterixis (hand flapping)
• Seizures
• Headache
• Dizziness or ataxia (loss of coordination)
• Visual disturbances

Diagnosis

Diagnosis is based on clinical evaluation of neurologic symptoms in the context of recent immunotherapy administration. Grading scales (e.g., ASTCT consensus) are used to assess severity. Laboratory tests may include cytokine level measurements, and neuroimaging (MRI/CT) can help rule out other causes. EEG may be performed if seizures are suspected.

Treatment Options

• Supportive care, including monitoring in a controlled setting
• Corticosteroids (e.g., dexamethasone) for severe symptoms
• Antiseizure medications if seizures occur
• Managing electrolyte imbalances or other metabolic disturbances
• Temporary hold or adjustment of immunotherapy dosing

Prognosis and Follow-Up

Most patients recover with appropriate management, though recovery time varies. Follow-up includes ongoing neurologic assessments and monitoring for recurrence. Long-term effects are uncommon but possible, particularly with severe or prolonged episodes.

Complications

• Prolonged confusion or cognitive impairment
• Refractory seizures
• Cerebral edema (rare, but serious)
• Delayed neurologic recovery

Lifestyle & Prevention

• No specific preventive measures outside of careful patient selection and monitoring during immunotherapy
• Maintaining hydration and stable metabolic status may support recovery
• Avoiding other neurotoxic medications during treatment when possible

When to Seek Professional Help

Seek immediate medical attention if symptoms such as severe headache, seizures, or significant confusion develop after immunotherapy. Early intervention improves outcomes.

Tips for Medical Coders

Document the timing of symptom onset relative to immunotherapy administration, as this is critical for coding accuracy. Include details on symptom severity and any interventions (e.g., steroid use) to support code assignment. Ensure documentation reflects the clinical course and resolution, as this impacts coding specificity.